The research objectives is to compare vitro 3D drug sensitivity test results of micro tumor (PTC) with the clinical outcomes of patients, evaluate the consistency between the test results of the technology platform and the clinical prognosis, and explore the decision-making value and guiding significance of this technology in assisting the precise treatment of colorectal cancer. The completion of this study will provide real-world data support for the clinical application of micro tumor (PTC) in vitro 3D drug sensitivity detection technology, and provide more valuable reference basis for realizing the individualization and accuracy of colorectal cancer treatment and improving the clinical benefit rate.
Age 18 ~ 75 years old, regardless of gender
Patients with colorectal cancer diagnosed by histopathology or cytology
Colorectal cancer patients who need adjuvant therapy after radical surgery and have not received neoadjuvant therapy
Having at least one assessable tumor focus
Patients diagnosed with metastasis
Patients who cannot obtain tumor samples
Pregnant and lactating women
Patients with poor compliance